Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01875705 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01875705 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 40 participants.
The verdict
NCT01875705, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0994 in patients with locally advanced or metastatic solid tumors. Patients will be enrolled in one of two stages: a dose-escalation stage (Stage I) or the subsequent expansion stage (Stage II). Stage I will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of GDC-0994 administered daily. Stage II will gather additional data on safety, tolerability, and pharmacokinetics of the recommended dose of GDC-0994 determined in Stage I.
Interventions
- DRUG GDC-0994
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-06-21 |
| Est. Completion | 2016-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01875705
The ClinicalTrials.gov registry entry for NCT01875705 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GDC-0994 is the first listed.
NCT01875705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01875705 about?
NCT01875705 is a clinical study titled "A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors". This is an open-label, multicenter, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0994 in patients with locally advanced or metastatic solid tumors. Patients will be enrolled in one of two stages: a dose-escalation stage (Stage I) or the subsequent expansion s...
What is the current status of trial NCT01875705?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-06-21. Estimated completion is 2016-09-23.
What interventions are being tested in trial NCT01875705?
The interventions under investigation include: GDC-0994 (DRUG).
Who is sponsoring clinical trial NCT01875705?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.